These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 29380440)

  • 21. Variables associated with the platelet count 6 weeks after autologous peripheral blood progenitor cell transplantation.
    Bolwell B; Goormastic M; Andresen S; Koo A; Wise K; Overmoyer B; Pohlman B; Kalaycio M
    Bone Marrow Transplant; 1998 Sep; 22(6):547-51. PubMed ID: 9758341
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Factors influencing engraftment in autologous peripheral hematopoetic stem cell transplantation (PBSCT).
    Ergene U; Cağirgan S; Pehlivan M; Yilmaz M; Tombuloğlu M
    Transfus Apher Sci; 2007 Feb; 36(1):23-9. PubMed ID: 17292672
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of immature platelet fraction and immature reticulocyte fraction as predictors of engraftment after hematopoietic stem cell transplantation.
    Morkis IV; Farias MG; Rigoni LD; Scotti L; Gregianin LJ; Daudt LE; Silla LM; Paz AA
    Int J Lab Hematol; 2015 Apr; 37(2):259-64. PubMed ID: 25066534
    [TBL] [Abstract][Full Text] [Related]  

  • 24. G-CSF primed peripheral blood progenitor cells in autologous bone marrow transplantation: parameters affecting bone marrow engraftment.
    Bolwell BJ; Fishleder A; Andresen SW; Lichtin AE; Koo A; Yanssens T; Burwell R; Baucco P; Green R
    Bone Marrow Transplant; 1993 Dec; 12(6):609-14. PubMed ID: 7511016
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low-dose lenograstim to enhance engraftment after autologous stem cell transplantation: a prospective randomized evaluation of two different fixed doses.
    Suh C; Kim HJ; Kim SH; Kim S; Lee SJ; Lee YS; Kim EK; Kim SB; Lee JS; Kim MW; Kim K; Yoon SS
    Transfusion; 2004 Apr; 44(4):533-8. PubMed ID: 15043569
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients.
    Lazarus HM; Koc ON; Devine SM; Curtin P; Maziarz RT; Holland HK; Shpall EJ; McCarthy P; Atkinson K; Cooper BW; Gerson SL; Laughlin MJ; Loberiza FR; Moseley AB; Bacigalupo A
    Biol Blood Marrow Transplant; 2005 May; 11(5):389-98. PubMed ID: 15846293
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival.
    van Besien K; Hari P; Zhang MJ; Liu HT; Stock W; Godley L; Odenike O; Larson R; Bishop M; Wickrema A; Gergis U; Mayer S; Shore T; Tsai S; Rhodes J; Cushing MM; Korman S; Artz A
    Haematologica; 2016 May; 101(5):634-43. PubMed ID: 26869630
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Feasibility of second hematopoietic stem cell transplantation using reduced-intensity conditioning with fludarabine and melphalan after a failed autologous hematopoietic stem cell transplantation.
    Hong JY; Choi MK; Kim DH; Kim SJ; Kim K; Kim WS; Chung CW; Kim HO; Min YH; Jang JH
    Transplant Proc; 2010 Nov; 42(9):3723-8. PubMed ID: 21094846
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factors predicting haematopoietic recovery in patients undergoing autologous transplantation: 11-year experience from a single centre.
    Bai L; Xia W; Wong K; Reid C; Ward C; Greenwood M
    Ann Hematol; 2014 Oct; 93(10):1655-64. PubMed ID: 24870941
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Allogeneic transplantation of positively selected peripheral blood CD34+ progenitor cells from matched related donors.
    Finke J; Brugger W; Bertz H; Behringer D; Kunzmann R; Weber-Nordt RM; Kanz L; Mertelsmann R
    Bone Marrow Transplant; 1996 Dec; 18(6):1081-6. PubMed ID: 8971376
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunological properties of bone marrow microenvironment 1 year after allogeneic hematopoietic stem cell transplantation.
    Ciomber A; Mitrus I; Fidyk W; Smagur A; Chwieduk A; Glowala-Kosinska M; Czerw T; Sobczyk-Kruszelnicka M; Mendrek W; Sadus-Wojciechowska M; Najda J; Holowiecki J; Giebel S
    Exp Hematol; 2016 Dec; 44(12):1172-1180.e1. PubMed ID: 27524270
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Viable CD34+/CD133+ blood progenitor cell dose as a predictor of haematopoietic engraftment in multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation.
    Hicks C; Wong R; Manoharan A; Kwan YL
    Ann Hematol; 2007 Aug; 86(8):591-8. PubMed ID: 17492259
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low transplant related mortality in older patients with hematologic malignancies undergoing autologous stem cell transplantation.
    Villela L; Sureda A; Canals C; Sanz MA; Martino R; Valcárcel D; Altés A; Briones J; Gómez M; Brunet S; Sierra J
    Haematologica; 2003 Mar; 88(3):300-5. PubMed ID: 12651269
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epidemiology, management, and outcome of invasive fungal disease in patients undergoing hematopoietic stem cell transplantation in China: a multicenter prospective observational study.
    Sun Y; Meng F; Han M; Zhang X; Yu L; Huang H; Wu D; Ren H; Wang C; Shen Z; Ji Y; Huang X
    Biol Blood Marrow Transplant; 2015 Jun; 21(6):1117-26. PubMed ID: 25840339
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gene and miRNA expression profiles of hematopoietic progenitor cells vary depending on their origin.
    Báez A; Martín-Antonio B; Piruat JI; Barbado MV; Prats C; Álvarez-Laderas I; Carmona M; Pérez-Simón JA; Urbano-Ispizua Á
    Biol Blood Marrow Transplant; 2014 May; 20(5):630-9. PubMed ID: 24462744
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I-II study of high-dose busulfan and cyclophosphamide followed by autologous peripheral blood stem cell transplantation for hematological malignancies: toxicities and hematopoietic recovery.
    Ballester OF; Agaliotis DP; Hiemenz JW; Janssen WE; Fields KK; Zorksy PE; Goldstein SC; Perkins JB; Elfenbein GJ
    Bone Marrow Transplant; 1996 Jul; 18(1):9-14. PubMed ID: 8831989
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of the CD34+ 38- cells in posttransplant hematopoietic recovery.
    Hénon P; Sovalat H; Bourderont D; Ojeda-Uribe M; Arkam Y; Wunder E; Raidot JP; Husseini F; Audhuy B
    Stem Cells; 1998; 16 Suppl 1():113-22. PubMed ID: 11012153
    [TBL] [Abstract][Full Text] [Related]  

  • 38. IGF-1-mediated osteoblastic niche expansion enhances long-term hematopoietic stem cell engraftment after murine bone marrow transplantation.
    Caselli A; Olson TS; Otsuru S; Chen X; Hofmann TJ; Nah HD; Grisendi G; Paolucci P; Dominici M; Horwitz EM
    Stem Cells; 2013 Oct; 31(10):2193-204. PubMed ID: 23818291
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells.
    Carlo-Stella C; Regazzi E; Andrizzi C; Savoldo B; Garau D; Montefusco E; Vignetti M; Mandelli F; Rizzoli V; Meloni G
    Haematologica; 1997; 82(3):291-6. PubMed ID: 9234574
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reassessing the definition of myeloid engraftment after autotransplantation: it is not necessary to see 0.5 x 10(9)/l neutrophils on 3 consecutive days to define myeloid recovery.
    Ali MY; Oyama Y; Monreal J; Winter J; Tallman M; Gordon LI; Williams S; Singhal S; Mehta J
    Bone Marrow Transplant; 2002 Dec; 30(11):749-52. PubMed ID: 12439697
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.